

Giulio Cavalli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1786351/publications.pdf>

Version: 2024-02-01

128
papers

5,622
citations

109137

35
h-index

85405

71
g-index

132
all docs

132
docs citations

132
times ranked

8190
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331.	2.2	808
2	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 483-492.	0.6	462
3	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1752-1760.	15.2	353
4	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49.	1.0	349
5	Suppression of inflammation and acquired immunity by IL-37. <i>Immunological Reviews</i> , 2018, 281, 179-190.	2.8	225
6	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1277-1285.	0.5	212
7	Anakinra Therapy for Non-cancer Inflammatory Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 1157.	1.6	198
8	The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1691-1695.	0.5	163
9	Interleukin 1 \pm : a comprehensive review on the role of IL-1 \pm in the pathogenesis and treatment of autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2021, 20, 102763.	2.5	140
10	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e253-e261.	2.2	140
11	Erdheim-Chester disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 223-229.	1.0	123
12	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , The, 2021, 3, e690-e697.	2.2	121
13	BRAF ^{V600E} -mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1596-1602.	0.5	94
14	Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. <i>Rheumatology</i> , 2015, 54, kev269.	0.9	91
15	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	1.6	89
16	MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1363-1368.	3.3	88
17	Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2313-2318.	3.3	87
18	Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. <i>Rheumatology</i> , 2016, 55, 2220-2229.	0.9	77

#	ARTICLE	IF	CITATIONS
19	Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 48-54.	1.6	75
20	Treating Life-Threatening Myocarditis by Blocking Interleukin-1*. <i>Critical Care Medicine</i> , 2016, 44, e751-e754.	0.4	75
21	2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 48-56.	0.5	71
22	Efficacy and safety of biological agents in adult-onset Still's disease. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 309-314.	0.6	66
23	Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. <i>European Journal of Internal Medicine</i> , 2021, 86, 34-40.	1.0	61
24	Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. <i>Frontiers in Immunology</i> , 2017, 8, 131.	2.2	53
25	Myocarditis: An Interleukin-1-Mediated Disease?. <i>Frontiers in Immunology</i> , 2018, 9, 1335.	2.2	53
26	Autophagy and Protein Secretion. <i>Journal of Molecular Biology</i> , 2020, 432, 2525-2545.	2.0	53
27	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021, 133, 104071.	1.1	49
28	Treating Pulmonary Silicosis by Blocking Interleukin 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 596-598.	2.5	48
29	Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 <i>in vivo</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1357-1362.	3.3	46
30	Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. <i>Autoimmunity Reviews</i> , 2015, 14, 352-357.	2.5	44
31	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 536-544.	0.5	44
32	FRI0506...EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILL'S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851.1-852.	0.5	43
33	Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. <i>Journal of Biological Chemistry</i> , 2018, 293, 14224-14236.	1.6	42
34	Oncogene-Induced Senescence as a New Mechanism of Disease: The Paradigm of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2014, 5, 281.	2.2	40
35	The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. <i>Cell Reports</i> , 2021, 35, 108955.	2.9	40
36	The right place for IL-1 inhibition in COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, 223-224.	5.2	39

#	ARTICLE	IF	CITATIONS
37	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1233.	2.2	37
38	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , 2018, 57, e11-e12.	1.0	36
39	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	1.6	35
40	Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. <i>RMD Open</i> , 2022, 8, e002168.	1.8	35
41	Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. <i>Annals of Internal Medicine</i> , 2018, 169, 819.	2.0	34
42	Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. <i>RMD Open</i> , 2022, 8, e002170.	1.8	32
43	Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 54.	1.6	31
44	Tocilizumab in patients with multisystem Erdheim-Chester disease. <i>Oncolmmunology</i> , 2017, 6, e1318237.	2.1	29
45	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 598308.	1.6	29
46	Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. <i>RMD Open</i> , 2022, 8, e002167.	1.8	28
47	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021, 12, 653950.	2.2	26
48	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 509-514.	1.6	24
49	Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , 2020, 59, 171-175.	0.9	23
50	Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 482-490.	0.6	22
51	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	1.2	21
52	Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series. <i>Arthritis and Rheumatology</i> , 2022, 74, 1302-1303.	2.9	21
53	Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. <i>International Journal of Cardiology</i> , 2018, 252, 21-23.	0.8	19
54	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , 2017, 239, 33.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. <i>Journal of Neurology</i> , 2018, 265, 273-284.	1.8	17
56	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2018, 7, e1440929.	2.1	17
57	Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. <i>Nature Communications</i> , 2021, 12, 4559.	5.8	17
58	Current treatment options and safety considerations when treating adult-onset Still's disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1549-1558.	1.0	15
59	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e11-e11.	0.5	15
60	Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2022, 74, 654-664.	2.9	15
61	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2016, 5, e1181244.	2.1	14
62	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1-6.	1.6	14
63	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e143-e146.	0.5	13
64	Diagnosing Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e19-e19.	0.5	10
65	Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1313-1322.	1.3	10
66	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021, 138, 1554-1569.	0.6	10
67	A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). <i>Frontiers in Medicine</i> , 2021, 8, 723506.	1.2	10
68	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. <i>Rheumatology</i> , 2022, 61, 4409-4419.	0.9	10
69	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , 2020, 47, 1780-1784.	1.0	9
70	Erdheim-Chester disease: An in vivo human model of M ϕ activation at the crossroad between chronic inflammation and cancer. <i>Journal of Leukocyte Biology</i> , 2020, 108, 591-599.	1.5	9
71	Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera. <i>Medicine (United States)</i> , 2016, 95, e3697.	0.4	8
72	3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 862-864.	0.5	8

#	ARTICLE	IF	CITATIONS
73	Publications Are Not the Finish Line: Focusing on Societal Rather Than Publication Impact. <i>Frontiers in Medicine</i> , 2018, 5, 314.	1.2	7
74	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.5	7
75	Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors. <i>Annals of Translational Medicine</i> , 2018, 6, S82-S82.	0.7	7
76	Charcot's arthropathy of the spine. <i>Arthritis and Rheumatism</i> , 2013, 65, 342-342.	6.7	5
77	THU0209â€¦Efficacy of anti-TNF therapy in 15 patients with refractory takayasuâ€™s arteritis: Long term unicentric follow-up. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 226.1-226.	0.5	5
78	Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case. <i>Modern Rheumatology</i> , 2016, 26, 276-277.	0.9	5
79	Advances in potential targeted therapies for Erdheim-Chester disease. <i>Expert Opinion on Orphan Drugs</i> , 0, , 1-8.	0.5	5
80	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.3	5
81	Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses. <i>Genome Medicine</i> , 2021, 13, 94.	3.6	5
82	A Bitter Effect: Thrombocytopenia Induced by a Quinidine-containing Beverage. <i>American Journal of Medicine</i> , 2014, 127, e1-e2.	0.6	4
83	Priorities of biomedical research. <i>International Journal of Cardiology</i> , 2017, 245, 256.	0.8	4
84	The course of action for effective anti-cytokine treatment in COVID-19. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1353-1354.	5.2	4
85	Charcotâ€™s Arthropathy of the Hip. <i>Journal of Rheumatology</i> , 2013, 40, 1770-1770.	1.0	3
86	SMAD4 gene mutation and risk of aortic dilation: Lessons from hereditary hemorrhagic telangiectasia. <i>International Journal of Cardiology</i> , 2017, 245, 145-146.	0.8	3
87	Letter by Campochiaro et al Regarding Article, â€œClinical Features, Management, and Outcomes of Immune Checkpoint Inhibitorâ€-Related Cardiotoxicityâ€. <i>Circulation</i> , 2018, 137, 2421-2422.	1.6	3
88	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	3
89	Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2014, 166, 470-470.	1.2	2
90	Orthopnea with platydeoxia secondary to prominent Eustachian valve. <i>Intensive Care Medicine</i> , 2015, 41, 918-919.	3.9	2

#	ARTICLE	IF	CITATIONS
91	Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e156-e157.	0.6	2
92	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2018, 25, 1.	0.5	2
93	AB0621â€¦GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS. , 2019, , .		2
94	A Novel Histiocytosis With Synovial and Skin Involvement. <i>Annals of Internal Medicine</i> , 2021, 174, 273-274.	2.0	2
95	POS1341â€¦TQCILIZUMAB FOR THE TREATMENT OF IMMUNE-RELATED ADVERSE EVENTS TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 953.1-953.	0.5	2
96	Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it?. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 2189-2190.	0.5	2
97	Myocarditis as a manifestation of Erdheimâ€“Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 243-245.	0.6	2
98	An enlightening scan. <i>European Journal of Internal Medicine</i> , 2015, 26, 68-69.	1.0	1
99	OP0092â€¦Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration and improves exercise tolerance. , 2017, , .		1
100	Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness. <i>European Journal of Internal Medicine</i> , 2020, 82, 23-24.	1.0	1
101	Canakinumab injection for the treatment of active Stillâ€™s disease, including adult-onset Stillâ€™s disease. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 77-86.	0.5	1
102	In the limelight: AA amyloidosis exposes TNF receptor-1 associated periodic syndrome. <i>Rheumatology</i> , 2021, 60, 5493-5494.	0.9	1
103	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	1
104	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
105	AB0742â€¦Pure peripheral giant cell arteritis: A systematic literature review of a poorly characterized clinical entity. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 681.2-681.	0.5	0
106	AB0746â€¦Juvenile temporal arteritis: Report of a case and review of the literature. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 681.6-681.	0.5	0
107	THU0386â€¦Efficacy of long-term treatment with biologic agents in refractory adult onset stillâ€™s disease: A single centre experience on 16 patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 286.1-286.	0.5	0
108	FRI0486â€¦Cardiac cine mri in erdheim-chester disease: data from a large italian cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A539.2-A539.	0.5	0

#	ARTICLE	IF	CITATIONS
109	THU0373â€¦Clinical presentation of erdheim-chester disease: Data from a cohort of 10 patients and review of the literature. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 281.3-282.	0.5	0
110	THU0372â€¦The Role of Echocardiography and Cardiac MRI in Erdheim-Chester Disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 311.1-311.	0.5	0
111	FRI0001â€¦Treating Experimental Arthritis with The Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 426.1-426.	0.5	0
112	FRI0325â€¦Prevalence of takayasu arteritis in young women with acute ischemic heart disease. , 2017, , .		0
113	168.â€¦GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
114	P087â€¦The anti-inflammatory cytokine interleukin 37 is an endogenous inhibitor of trained immunity. , 2019, , .		0
115	P105â€¦Identification of rare coding variants in IL-1-related pathways in patients with adult-onset stillâ€™s disease. , 2019, , .		0
116	THU0570â€¦EFFICACY AND SAFETY OF ANAKINRA IN THE TREATMENT OF AUTOIMMUNE MYOCARDITIS. , 2019, , .		0
117	Autophagy in the regulation of protein secretion in immune cells. , 2020, , 141-173.		0
118	Anakinra in COVIDâ€™19â€™How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarroâ€™n et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 549-549.	2.9	0
119	The choice of early treatment and the impact of future relapses in adult onset Stillâ€™s disease. <i>Rheumatology</i> , 2021, 60, 2500-2501.	0.9	0
120	POS1347â€¦IMPACT OF CANAKINUMAB AND ANAKINRA ON PATIENT-REPORTED OUTCOMES IN ADULT-ONSET STILLâ€™S DISEASE PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 955.3-956.	0.5	0
121	POS0370â€¦TYPE I INTERFERON PATHWAY ASSAYS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES - SYSTEMATIC LITERATURE REVIEW (SLR) AND DEVELOPMENT OF CONSENSUS TERMINOLOGY FROM A EULAR TASKFORCE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 415-415.	0.5	0
122	POS1336â€¦RETROPERITONEAL FIBROSIS IN ERDHEIM-CHESTER DISEASE HAS UNIQUE PRESENTING AND PROGNOSTIC FEATURES: A SINGLE CENTRE RETROSPECTIVE COMPARATIVE COHORT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 950-951.	0.5	0
123	AB1159â€¦Virus-negative lymphocytic myocarditis: clinical and diagnostic features from a monocentric italian cohort. , 2018, , .		0
124	AB1135â€¦Cardiac magnetic resonance findings in patients with biopsy-proven virus-negative lymphocytic myocarditis. , 2018, , .		0
125	FRI0484â€¦SAFETY PROFILE, CLINICAL AND RADIOLOGICAL EFFICACY OF ANAKINRA, TARGETED AND COMBINED TREATMENT IN ERDHEIM-CHESTER DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 839.1-840.	0.5	0
126	SAT0519â€¦DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILLâ€™S DISEASE IN THE PRE-CANAKINUMAB ERA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1215-1216.	0.5	0

#	ARTICLE	IF	CITATIONS
127	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
128	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0